24 completed, 6 unknown, 3 terminated, 2 recruiting. 11 Phase 1, 10 Phase 4, 6 Phase 3, 4 Not applicable, 2 Phase 2.
Follow Torsemide: new trials by email Literature Review of Torsemide trials Research Report on Torsemide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions: Torasemide tablet 10 mg, Unat® 10 tablets (Torasemide 10 mg) - Healthy Adult Male and Female Volunteers | Phase 1 | Recruiting | Berlin-Chemie AG Menarini Group | 26 | 2025-09-05 | 2026-01-14 |
| Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet - Bioequivalence Study in Healthy Subjects, PK/PD | Phase 3 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2025-07-01 | 2026-03-06 |
| Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets - Bioavailability Heathy Volunteers | Phase 3 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2025-06-15 | 2026-03-09 |
| A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs torsemide - Heart Failure | Phase 4 | Withdrawn | Sarfez Pharmaceuticals, Inc. | 2025-01-15 | 2026-04-27 | |
| EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) Reprieve Decongestion Management System, Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide) - Acute Decompensated Heart Failure | Not applicable | Completed | Reprieve Cardiovascular, Inc | 12 | 2024-05-17 | 2025-03-10 |
| A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril Captopril 12.5 Mg, Sodium bicarbonate 4 G, Torsemide 20 MG - Hypertension | Phase 1 | Completed | Seoul National University Hospital | 12 | 2024-02-28 | 2025-05-30 |
| Optimal Medical Treatment of Difficult-to-treat Hypertension Phase C: Eplerenone, Phase C: Spironolactone, Phase C: Torasemide - Hypertension | Phase 4 | Unknown | National Institute of Cardiology, Warsaw, Poland | 2500 | 2023-10-20 | 2024-02-23 |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation Captopril Tablets, Metoprolol Oral Tablet, Spironolactone Tablets - Congenital Mitral Insufficiency | Unknown | China National Center for Cardiovascular Diseases | 122 | 2022-04-01 | 2023-09-15 | |
| Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair Captopril Tablets, Metoprolol Oral Tablet, Spironolactone Tablets - Congenital Mitral Insufficiency | Unknown | China National Center for Cardiovascular Diseases | 164 | 2022-04-01 | 2023-09-15 | |
| Study of Drug Therapy for Pediatric Heart Failure Captopril Tablets, Metoprolol Oral Tablet, Spironolactone Tablets - Heart Failure Congenital | Unknown | China National Center for Cardiovascular Diseases | 200 | 2022-01-01 | 2023-09-15 | |
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts Furosemide, Torsemide, Bumetanide - Heart Failure, Congestive | Phase 4 | Recruiting | Heart Center Research, LLC | 80 | 2021-07-08 | 2024-01-29 |
| Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide CHF Patients: ER Torsemide 40 mg, CHF Patients: Furosemide 40 mg - Body Weight Changes | Phase 1 | Terminated | Sarfez Pharmaceuticals, Inc. | 20 | 2021-06-30 | 2026-04-24 |
| Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions Torasemide tablet 10 mg, Toradiur® tablet 10 mg - Bioequivalence | Phase 1 | Completed | Pharmtechnology LLC | 26 | 2021-06-05 | 2023-06-29 |
| Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment Torasemide, Spironolactone - Hypertension, Genetic Predisposition | Phase 3 | Completed | Ospedale San Raffaele | 38 | 2021-02-15 | 2024-05-16 |
| Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure Furosemide, Torsemide - Heart Failure | Phase 3 | Completed | Yale University | 47 | 2021-02-08 | 2024-10-15 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure Torsemide, Furosemide - Heart Failure | Phase 3 | Completed | Duke University | 2973 | 2018-07-11 | 2025-10-16 |
| Weight-Based Torsemide Dosing in Subjects With Heart Failure Torsemide, Standard Outpatient Heart Failure Management - Heart Failure | Phase 4 | Completed | New York City Health and Hospitals Corporation | 52 | 2018-04-17 | 2022-03-15 |
| Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects Demadex 20mg Tablet, ER Torsemide 20mg Tablet - Congestive Heart Failure, Chronic Kidney Diseases | Phase 1 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2017-06-19 | 2018-04-18 |
Showing 20 of 36. Sign in to see all of them.
Heart Failure (9) · Hypertension (9) · Edema (2) · Heart Defects, Congenital (2) · Mitral Valve Insufficiency (2) · Renal Insufficiency, Chronic (2) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · Fasting (1) · Genetic Predisposition to Disease (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Pre-Eclampsia (1) · Renal Insufficiency (1)
Sarfez Pharmaceuticals, Inc. (5) · China National Center for Cardiovascular Diseases (3) · Par Pharmaceutical, Inc. (2) · Roxane Laboratories (2) · Berlin-Chemie AG Menarini Group (1) · Boehringer Ingelheim (1) · Duke University (1) · Ferrer Internacional S.A. (1) · Heart Center Research, LLC (1) · Hebei Medical University (1) · Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH (1) · Matthias Schwab (1) · Medical University of Warsaw (1) · Merck Sharp & Dohme LLC (1) · NHS Greater Glasgow and Clyde (1)
United States (13) · China (4) · Germany (3) · Poland (3) · India (2) · Italy (1) · Kazakhstan (1) · Netherlands (1) · Russia (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Shoujun Li, MD (3) · Dennis Morrison, DO (2) · Eric Masson (2) · Salim Shah, PhD, JD (2) · Adam P Bress, PharmD, MS (1) · Alex Roca, MD, PhD (1) · Alexander Khokhlov (1) · Alexander O Sherenkov, MD, PhD (1) · Alexander V Orlov-Morozov, MD, PhD (1) · Andrei Y Baranovsky, MD, PhD (1) · Angel Cano, MD (1) · Angela Felip, MD, PhD (1) · Anil K, MD (1) · Antonio Coca, MD, PhD (1) · Blas Gil, MD (1)
PMID 39196651, PMID 11705426, PMID 19407805, PMID 21617110, PMID 21884956, PMID 25636696, PMID 26344676, PMID 26399404, PMID 27666126, PMID 27692976, PMID 27825374, PMID 28114980, PMID 30303905, PMID 32973880, PMID 33084880, PMID 33714745, PMID 33891615, PMID 35181553, PMID 35460884, PMID 36648467, PMID 37212600, PMID 38436075, PMID 38745502, PMID 39077768, PMID 40295876, PMID 42419438
1IK2CX002368-01A1 (1), U01HL125511 (1)